Provided by Tiger Trade Technology Pte. Ltd.

ProMIS Neurosciences Inc

18.21
+1.217.12%
Post-market: 18.350.1400+0.77%16:18 EDT
Volume:37.63K
Turnover:654.97K
Market Cap:39.20M
PE:-0.91
High:18.44
Open:16.56
Low:16.04
Close:17.00
52wk High:39.75
52wk Low:6.27
Shares:2.15M
Float Shares:1.02M
Volume Ratio:0.67
T/O Rate:3.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-20.0495
EPS(LYR):2.68
ROE:-355.80%
ROA:-85.38%
PB:4.27
PE(LYR):6.79

Loading ...

BRIEF-Plasma pTau Identified as Key Early Endpoint in Alzheimer's Research

Reuters
·
Dec 01, 2025

ProMIS Neurosciences Announces Interim Phase 1b Trial Readout for PMN310 in Alzheimer's Disease Set for Q2 2026

Reuters
·
Dec 01, 2025

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma Ptau as a Predictive Early Endpoint in Alzheimer’s Trials, Supporting Its Ongoing Phase 1B Precise-Ad Trial With Pmn310

THOMSON REUTERS
·
Dec 01, 2025

ProMIS Neurosciences CEO to Join Fireside Chat at Evercore Healthcare Conference

Reuters
·
Dec 01, 2025

NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM

Reuters
·
Nov 27, 2025

Promis Neurosciences Inc trading halted, news pending

TIPRANKS
·
Nov 27, 2025

Analysts Offer Insights on Healthcare Companies: ProMIS Neurosciences (PMN) and Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Nov 26, 2025

Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher

Benzinga
·
Nov 24, 2025

ProMIS Neurosciences Announces 1-for-25 Reverse Stock Split

Reuters
·
Nov 24, 2025

ProMIS Neurosciences Announces Reverse Stock Split

THOMSON REUTERS
·
Nov 24, 2025

ProMIS Neurosciences Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
Nov 21, 2025

PTS Announces Official Launch of PMN on Republic -- Japan's First Compliant STO Offered in the United States

prnewswire
·
Nov 21, 2025

ProMIS Neurosciences Inc. held special shareholder meeting

Reuters
·
Nov 19, 2025

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY) and ProMIS Neurosciences (PMN)

TIPRANKS
·
Nov 19, 2025

ProMIS Neurosciences Is Maintained at Buy by Guggenheim

Dow Jones
·
Nov 18, 2025

ProMIS Neurosciences price target lowered to $5 from $6 at Guggenheim

TIPRANKS
·
Nov 18, 2025

ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial

Reuters
·
Nov 12, 2025

ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending

Reuters
·
Nov 12, 2025

PTS to Launch Japan-Origin Bitcoin Mining Investment Product via Republic Platform Under U.S. Regulation

prnewswire
·
Oct 29, 2025

ProMIS Neurosciences Inc. Files Initial Statement of Beneficial Ownership for Director Alex Slanix Paul

Reuters
·
Oct 25, 2025